Introduction: In the discussion of genitourinary malignancies encompassing prostate cancer, bladder cancer, renal cell carcinoma (RCC), and urothelial cancer, significant strides have been made in treatment options. Among the latest innovations are antibody-drug conjugates (ADCs), offering a promising avenue by combining the precision of monoclonal antibodies with the cytotoxic potency of chemotherapy. This blog explores the mechanisms of action, clinical trials, and potential benefits of ADCs in managing genitourinary cancers.   Understanding Antibody-Drug Conjugates: Antibody-drug conjugates (ADCs) represent a sophisticated class of therapeutics designed to target cancer cells with precision while minimizing systemic toxicity. The components of ADCs include: Monoclonal…